The scleroderma kidney: Progress in risk factors, therapy, and prevention

Current Rheumatology Reports

Volumn 13, Issue 1, 2011, Pages 37-43

  Bussone, Guillaume ^a   Bérezné, Alice ^a   Pestre, Vincent ^a   Guillevin, Loïc ^a   Mouthon, Luc ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

Prevention; Renal crisis; Risk factors; Systemic sclerosis; Treatment

Indexed keywords

AUTOANTIBODY; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DNA DIRECTED RNA POLYMERASE III ANTIBODY; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; ILOPROST; IMMUNOGLOBULIN; MINOXIDIL; NICARDIPINE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; PROSTACYCLIN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ARTICLE; BLOOD PRESSURE MONITORING; BONE NECROSIS; DIALYSIS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUNG FIBROSIS; MALIGNANT HYPERTENSION; MORTALITY; NEPHROTOXICITY; OLIGURIA; PLASMAPHERESIS; PROGNOSIS; PROTEINURIA; PULMONARY HYPERTENSION; RISK FACTOR; SCLERODERMA RENAL CRISIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; HYPERTENSION, RENAL; KIDNEY DISEASES; PROGNOSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 79551525327     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0145-7     Document Type: Article

References (50)

1. VD Steen TA Medsger Jr 2000 Severe organ involvement in systemic sclerosis with diffuse scleroderma Arthritis Rheum 43 2437 2444 1:STN:280:DC%2BD3M%2FktFequw%3D%3D 10.1002/1529-0131(200011)43:11<2437::AID- ANR10>3.0.CO;2-U 11083266
2. Mouthon L, Berezne A, Bussone G, et al.: Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy Immunol 2009. doi: 10.1007/s12016-009-8191-5.
3. VD Steen TA Medsger 2007 Changes in causes of death in systemic sclerosis, 1972-2002 Ann Rheum Dis 66 940 944 10.1136/ard.2006.066068 17329309 (Pubitemid 46999798)
4. VD Steen JP Costantino AP Shapiro, et al. 1990 Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors Ann Intern Med 113 352 357 1:STN:280:DyaK3czktlWksA%3D%3D 2382917
5. H Penn AJ Howie EJ Kingdon, et al. 2007 Scleroderma renal crisis: patient characteristics and long-term outcomes QJM 100 485 494 1:STN:280: DC%2BD2svjtVWgtQ%3D%3D 10.1093/qjmed/hcm052 17601770 (Pubitemid 47241915)
6. L Teixeira L Mouthon A Mahr, et al. 2008 Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients Ann Rheum Dis 67 110 116 1:STN:280:DC%2BD2sjjslKmtg%3D%3D 10.1136/ard.2006.066985 17557890 The authors describe the presentation and outcome of 50 patients with SRC in a French cohort. SRC is associated with severe morbidity and mortality. In the 6 months prior to SRC onset or to the first visit, high-dose corticosteroids (= 15 mg/d of prednisone) were administered significantly more frequently in SRC patients (36%) than in controls (12%) (OR, 4.37). Multivariate analyses retained age older than 53 years and normal blood pressure as independent predictors of decreased dialysis-free survival
7. UA Walker A Tyndall L Czirjak, et al. 2007 Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database Ann Rheum Dis 66 754 763 1:STN:280: DC%2BD2s3pvFaksg%3D%3D 10.1136/ard.2006.062901 17234652 (Pubitemid 46846694)
8. DJ Helfrich B Banner VD Steen, et al. 1989 Normotensive renal failure in systemic sclerosis Arthritis Rheum 32 1128 1134 1:STN:280:DyaL1MznsVeltA%3D%3D 10.1002/anr.1780320911 2775321
9. PJ DeMarco MH Weisman JR Seibold, et al. 2002 Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial Arthritis Rheum 46 2983 2989 1:CAS:528:DC%2BD38XptlSks7w%3D 10.1002/art.10589 12428241 (Pubitemid 35315892)
10. JG Walker MJ Ahern MD Smith, et al. 2003 Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment Intern Med J 33 216 220 1:STN:280:DC%2BD3s3jtFWmsA%3D%3D 10.1046/j.1445-5994.2003.00358.x 12752889 (Pubitemid 36718377)
11. VD Steen TA Medsger TA Osial, et al. 1984 Factors predicting development of renal involvement in progressive systemic sclerosis Am J Med 76 779 786 1:STN:280:DyaL2c3gtVWqtA%3D%3D 10.1016/0002-9343(84)90986-0 6372452
12. PJ Clements EL Hurwitz WK Wong, et al. 2000 Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial Arthritis Rheum 43 2445 2454 1:STN:280: DC%2BD3M%2FktFCjsg%3D%3D 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3. 0.CO;2-Q 11083267
13. VD Steen 1994 Renal involvement in systemic sclerosis Clin Dermatol 12 253 258 1:STN:280:DyaK2czls1Okug%3D%3D 10.1016/S0738-081X(94)90329-8 8076263 (Pubitemid 24198731)
14. VD Steen 2003 Scleroderma renal crisis Rheum Dis Clin North Am 29 315 333 10.1016/S0889-857X(03)00016-4 12841297
15. SI Nihtyanova CP Denton 2008 Current approaches to the management of early active diffuse scleroderma skin disease Rheum Dis Clin North Am 34 161 179 10.1016/j.rdc.2007.11.005 18329538 (Pubitemid 351329458)
16. L Shand M Lunt S Nihtyanova, et al. 2007 Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model Arthritis Rheum 56 2422 2431 10.1002/art.22721 17599771 (Pubitemid 47173590)
17. M Lam SP Ballou 1992 Reversible scleroderma renal crisis after cocaine use N Engl J Med 326 1435 1:STN:280:DyaK383js1Ogtw%3D%3D 1569994
18. PJ Clements PA Lachenbruch M Sterz, et al. 1993 Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients Arthritis Rheum 36 75 83 1:STN:280:DyaK3s7ktlOqsQ%3D%3D 10.1002/art.1780360113 8424841 (Pubitemid 23048682)
19. CP Denton P Sweny A Abdulla, et al. 1994 Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases Br J Rheumatol 33 90 92 1:STN:280:DyaK2c3hsFShsQ%3D%3D 10.1093/rheumatology/33.1.90 8162467
20. G Filaci M Cutolo M Scudeletti, et al. 1999 Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy Rheumatology (Oxford) 38 992 996 1:CAS:528:DyaK1MXntlWlsrg%3D 10.1093/rheumatology/38.10.992 (Pubitemid 29505082)
21. JC Ruiz F Val AL de Francisco, et al. 1991 Progressive systemic sclerosis and renal transplantation: a contraindication to ciclosporin Nephron 59 330 332 1:STN:280:DyaK38%2Fms1Sqtg%3D%3D 10.1159/000186579 1956502
22. VD Steen TA Medsger Jr 1998 Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis Arthritis Rheum 41 1613 1619 1:CAS:528: DyaK1cXmsVChtbc%3D 10.1002/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2- O 9751093 (Pubitemid 28459919)
23. H Kobayashi T Nishimaki S Kaise, et al. 1999 Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis Clin Rheumatol 18 425 427 1:STN:280:DyaK1Mvlt1WqsA%3D%3D 10.1007/s100670050132 10524561 (Pubitemid 29479775)
24. •• Mouthon L, Mehrenberger M, Teixeira L, et al.: Endothelin-1 expression in scleroderma renal crisis. Human Pathol 2010. doi: 10.1016/j.humpath.2010.05.018. The authors investigated the role of ET-1 in the pathogenesis of SRC in 14 patients with SSc. A pattern of endothelial staining for ET-1 in both glomeruli and arteriolar lesions appears to be specific for SRC. This suggests that ET-1 might be targeted in this condition.
25. I Borcsok HU Schairer U Sommer, et al. 1998 Glucocorticoids regulate the expression of the human osteoblastic endothelin A receptor gene J Exp Med 188 1563 1573 1:CAS:528:DyaK1cXntFOmsbs%3D 10.1084/jem.188.9.1563 9802968 (Pubitemid 28516101)
26. M Kuwana J Kaburaki T Mimori, et al. 1993 Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis J Clin Invest 91 1399 1404 1:CAS:528:DyaK3sXisFeit7s%3D 10.1172/JCI116343 8473491
27. M Kuwana Y Okano JP Pandey, et al. 2005 Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis Arthritis Rheum 52 2425 2432 1:CAS:528:DC%2BD2MXpslGht78%3D 10.1002/art.21232 16052583 (Pubitemid 41117428)
28. GR Harvey S Butts AL Rands, et al. 1999 Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis Clin Exp Immunol 117 395 402 1:CAS:528:DyaK1MXlsFKhsr0%3D 10.1046/j.1365-2249.1999.00964. x 10444276 (Pubitemid 29343616)
29. CC Bunn CP Denton X Shi-Wen, et al. 1998 Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis Br J Rheumatol 37 15 20 1:STN:280:DyaK1c7kvVahtw%3D%3D 10.1093/rheumatology/37.1.15 9487245
30. VD Steen 2005 Autoantibodies in systemic sclerosis Semin Arthritis Rheum 35 35 42 1:CAS:528:DC%2BD2MXntVOisL0%3D 10.1016/j.semarthrit.2005.03.005 16084222 (Pubitemid 41111469)
31. O Meyer L De Chaisemartin P Nicaise-Roland, et al. 2010 Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study J Rheumatol 37 125 130 1:CAS:528:DC%2BC3cXitVajt7k%3D 10.3899/jrheum.090677 19918031
32. V Codullo I Cavazzana C Bonino, et al. 2009 Serologic profile and mortality rates of scleroderma renal crisis in Italy J Rheumatol 36 1464 1469 10.3899/jrheum.080806 19487262 The authors analyzed the characteristics of 46 patients with SRC. Anti-RNA-polymerase III antibodies were detected in seven patients (15%), and the proportion of patients in the anti-RNA-polymerase III group who developed SRC early in the course of SSc was significantly higher. Survival rates significantly differed according to the autoantibody profile, as they were lower in the antitopoisomerase 1 group than in the anti-RNA-polymerase III group
33. S Emilie C Goulvestre A Bérezné, et al. 2010 Anti-RNA polymerase III antibodies and scleroderma renal crisis: evaluation of a French cohort Ann Rheum Dis 69 Suppl 3 251
34. OC Meyer N Fertig M Lucas, et al. 2007 Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis J Rheumatol 34 104 109 17117486
35. S Jacobsen S Ullman GQ Shen, et al. 2001 Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis J Rheumatol 28 2454 2459 1:STN:280:DC%2BD3Mnmt1Oqtg%3D%3D 11708418
36. SI Nihtyanova JC Parker CM Black, et al. 2009 A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis Rheumatology (Oxford) 48 1218 1221 1:CAS:528:DC%2BD1MXht12ns7fN 10.1093/rheumatology/kep215 The authors analyzed serial anti-RNA-polymerase III antibody levels and explored the relationship with clinical features and disease outcome. Anti-RNA-polymerase III antibodies were strongly associated with SRC, but no significant association was found between absolute levels of anti-RNA-polymerase III antibodies and the development of internal organ complications. Anti-RNA-polymerase III antibody level changes correlated with changes in skin score
37. ET Zawada Jr PJ Clements DA Furst, et al. 1981 Clinical course of patients with scleroderma renal crisis treated with captopril Nephron 27 74 78 10.1159/000182028 7022235
38. RH Thurm JC Alexander 1984 Captopril in the treatment of scleroderma renal crisis Arch Intern Med 144 733 735 1:STN:280:DyaL2c7nslKqsw%3D%3D 10.1001/archinte.144.4.733 6370160 (Pubitemid 14173516)
39. VD Steen TA Medsger 2000 Long-term outcomes of scleroderma renal crisis Ann Intern Med 133 600 603 1:STN:280:DC%2BD3M%2Fht1Sisw%3D%3D 11033587
40. H Akoglu GK Atilgan R Ozturk, et al. 2009 A "silent" course of normotensive scleroderma renal crisis: case report and review of the literature Rheumatol Int 29 1223 1229 10.1007/s00296-008-0807-1 19048256
41. G Bussone A Berezne L Mouthon 2009 Infectious complications of systemic sclerosis Presse Med 38 291 302 10.1016/j.lpm.2008.11.003 19062246
42. HJ Anders B Wiebecke C Haedecke, et al. 1999 MPO-ANCA-positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease? Am J Kidney Dis 33 e3 1:STN:280:DyaK1M3ht1Wqtw%3D%3D 10.1016/S0272-6386(99)70244-1 10196034
43. VD Steen A Syzd JP Johnson, et al. 2005 Kidney disease other than renal crisis in patients with diffuse scleroderma J Rheumatol 32 649 655 15801020
44. CD Smith RD Smith JH Korn 1984 Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor MK, 421 (Enalapril) in captopril-intolerant patients Arthritis Rheum 27 826 828 1:STN:280:DyaL2c3ls1yrsg%3D%3D 10.1002/art.1780270716 6331462
45. FJ Caskey EJ Thacker PA Johnston, et al. 1997 Failure of losartan to control blood pressure in scleroderma renal crisis Lancet 349 620 1:STN:280:DyaK2s3htVKktA%3D%3D 10.1016/S0140-6736(05)61568-1 9057740 (Pubitemid 27101895)
46. CP Denton CM Black 2004 Scleroderma-clinical and pathological advances Best Pract Res Clin Rheumatol 18 271 290 1:CAS:528:DC%2BD2cXkt1Cnsbg%3D 15158741
47. CP Denton CM Black 2000 Scleroderma and related disorders: therapeutic aspects Baillieres Best Pract Res Clin Rheumatol 14 17 35 10.1053/berh.1999.0075 10882212 (Pubitemid 30353022)
48. N Dhaun IM MacIntyre CO Bellamy, et al. 2009 Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney Am J Kidney Dis 54 726 731 1:CAS:528:DC%2BD1MXhtlCgs7jP 10.1053/j.ajkd.2009.02.015 19376621
49. H Penn A Burns CM Black, et al. 2009 An open label trial of the endothelin receptor antagonist bosentan in scleroderma renal crisis (BIRD-1) [abstract] Arthritis Rheum 60 Suppl 10 451
50. PT Pham PC Pham GM Danovitch, et al. 2005 Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature Am J Transplant 5 2565 2569 10.1111/j.1600-6143.2005. 01035.x 16162209